Management of Acute Asthma Exacerbation in CKD Patients on Hemodialysis

Initial Assessment and Treatment

The American Heart Association recommends providing oxygen therapy (40-60%) to all patients with severe asthma, even those with normal oxygenation, as successful bronchodilator treatment may initially worsen ventilation-perfusion mismatch 1
The initial management for a CKD patient on hemodialysis experiencing an acute exacerbation of bronchial asthma should include oxygen therapy, inhaled short-acting beta-agonists (albuterol), and systemic corticosteroids, with careful attention to medication dosing due to renal impairment 1, 2
Administer nebulized albuterol 5 mg or terbutaline 10 mg via oxygen-driven nebulizer as first-line treatment 3
Add nebulized ipratropium bromide as it produces clinically modest improvement in lung function when combined with short-acting beta-agonists 1
Administer systemic corticosteroids early (prednisolone 30-60 mg orally or hydrocortisone 200 mg intravenously) as they are the only effective treatment for the inflammatory component of asthma 1, 2

Monitor blood pressure closely as many CKD patients have hypertension, and beta-agonists may cause further elevation 4, 5
Reduce the dose of epinephrine in local anesthetics if needed due to risk of increasing blood pressure in CKD patients 5
Consider consulting the patient's nephrologist regarding medication dosing adjustments, particularly for drugs that are renally excreted 4, 5
Avoid nephrotoxic drugs and adjust dosing intervals for medications according to the degree of renal impairment 4

Oral corticosteroids do not require dose adjustment in renal failure and can be given at standard doses (prednisolone 30-40 mg daily) 6
For severe exacerbations, consider intravenous magnesium sulfate (2g over 20 minutes) as an adjunctive therapy 2, 7

Assess respiratory rate, heart rate, ability to complete sentences, and peak expiratory flow (PEF) to determine severity 3
Consider life-threatening features: silent chest, cyanosis, feeble respiratory effort, bradycardia, confusion, exhaustion, or coma 3
Monitor response to treatment within 15-30 minutes after nebulizer administration 3
For patients with severe exacerbations, monitor arterial blood gases, but recognize this may be complicated in dialysis patients 1

For severe exacerbations not responding to initial treatment, consider magnesium sulfate (2g IV over 20 minutes) 2, 7
Consider heliox-driven albuterol nebulization in patients with severe exacerbations not responding to standard therapy 2
For life-threatening exacerbations, prepare for possible intubation and mechanical ventilation with a "permissive hypercapnia" strategy to minimize barotrauma 2

Consider hospital admission for any life-threatening features or if features of acute severe asthma persist after initial treatment 3
Lower the threshold for admission in patients with afternoon/evening presentations, recent nocturnal symptoms, recent hospital admissions, or previous severe attacks 3
Ensure follow-up within 24-48 hours after discharge for patients not requiring admission 2, 3

Do not delay administration of systemic corticosteroids as their anti-inflammatory effects may not be apparent for 6-12 hours 1
Avoid aminoglycoside antibiotics and tetracyclines in CKD patients due to their nephrotoxicity 4
Be aware that continuous administration of nebulized albuterol may be more effective than intermittent administration in a subset of patients with severe exacerbations 1
Recognize that intubation in severe asthma is challenging and should be performed semi-electively before respiratory arrest occurs 2